Telomerase inhibition, oligonucleotides, and clinical trials

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2′-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalOncogene
Volume21
Issue number4 REV. ISS. 1
DOIs
StatePublished - Jan 21 2002

Fingerprint

Telomerase
Oligonucleotides
Clinical Trials
Neoplasms
Telomere
Pharmacokinetics
Cell Proliferation
Drug Therapy

Keywords

  • 2′-methoxyethyl RNA
  • Oligonucleotides
  • Telomerase
  • Telomere

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Telomerase inhibition, oligonucleotides, and clinical trials. / Corey, David R.

In: Oncogene, Vol. 21, No. 4 REV. ISS. 1, 21.01.2002, p. 631-637.

Research output: Contribution to journalArticle

Corey, David R. / Telomerase inhibition, oligonucleotides, and clinical trials. In: Oncogene. 2002 ; Vol. 21, No. 4 REV. ISS. 1. pp. 631-637.
@article{4d9c8dc4f87c4d3dad225a3550d9c1f4,
title = "Telomerase inhibition, oligonucleotides, and clinical trials",
abstract = "Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2′-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.",
keywords = "2′-methoxyethyl RNA, Oligonucleotides, Telomerase, Telomere",
author = "Corey, {David R.}",
year = "2002",
month = "1",
day = "21",
doi = "10.1038/sj/onc/1205063",
language = "English (US)",
volume = "21",
pages = "631--637",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "4 REV. ISS. 1",

}

TY - JOUR

T1 - Telomerase inhibition, oligonucleotides, and clinical trials

AU - Corey, David R.

PY - 2002/1/21

Y1 - 2002/1/21

N2 - Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2′-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.

AB - Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the efficacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative effects will probably require weeks to become apparent. This review will describe the properties of 2′-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.

KW - 2′-methoxyethyl RNA

KW - Oligonucleotides

KW - Telomerase

KW - Telomere

UR - http://www.scopus.com/inward/record.url?scp=0037148329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037148329&partnerID=8YFLogxK

U2 - 10.1038/sj/onc/1205063

DO - 10.1038/sj/onc/1205063

M3 - Article

VL - 21

SP - 631

EP - 637

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 4 REV. ISS. 1

ER -